Parion Sciences Receives 2015 Life Sciences Award as “Best Late Stage Product Development” Company   DURHAM, N.C., May 22, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it was awarded the...

DiamiR Announces Publication and Discusses Merits of Universal Screening Test Based on Organ-Enriched microRNA Signatures MONMOUTH JUNCTION, NJ--(Marketwired - November 03, 2014) - DiamiR Biosciences Corp., a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today the...

Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...

Actress Anjelica Huston's Words Greet Scientists As They Ponder Deadly Lung Disease Affecting Horses, Dogs, Cats, Humans LOUISVILLE, Ky., April 24, 2014 (GLOBE NEWSWIRE) -- Actress Anjelica Huston's words will greet researchers from around the globe when they meet later this week to better understand Pulmonary Fibrosis...

Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013 La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the...